{"title":"R-CHOP治疗非人类免疫缺陷病毒感染的非霍奇金b细胞淋巴瘤肺囊虫性肺炎的研究进展","authors":"Fengping Zhou, Shenhe Jin, Jin Zhang","doi":"10.36468/pharmaceutical-sciences.1185","DOIUrl":null,"url":null,"abstract":"Increasing numbers of non-human immunodeficiency virus-infected individuals with non-Hodgkin's B cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone have been diagnosed with Pneumocystis pneumonia. Pneumocystis pneumonia is a serious infection with a high mortality rate and rapid progression. In these patients, the incidence of Pneumocystis pneumonia varied from 1.4 % to 13 %, according to a comprehensive literature review. The major clinical symptoms were dry cough, fever, tightness in the chest, progressive dyspnea and hypoxemia. The standard method of diagnosis is Pneumocystis detection in broncho alveolar lavage fluid and high-resolution computed tomography can be detected in diffuse interstitial infiltration of both lungs. Trimethoprim/sulfamethoxazole is the main treatment for Pneumocystis pneumonia and most studies have shown that preventive use of trimethoprim/ sulfamethoxazole can help reduce the incidence of Pneumocystis pneumonia. In order to improve the accuracy of diagnosis and the prompt initiation of therapy for treatment and prevention to improve outcomes in these patients, a deeper knowledge of the relationship between rituximab use and the incidence of Pneumocystis pneumonia and the characteristics of Pneumocystis pneumonia in non-human immunodeficiency virusinfected patients with lymphoma is required.","PeriodicalId":13292,"journal":{"name":"Indian Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Progress in the Research of Pneumocystis Pneumonia in Non-Human Immunodeficiency Virus-Infected Non-Hodgkin's B-Cell Lymphoma Treated With R-CHOP\",\"authors\":\"Fengping Zhou, Shenhe Jin, Jin Zhang\",\"doi\":\"10.36468/pharmaceutical-sciences.1185\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Increasing numbers of non-human immunodeficiency virus-infected individuals with non-Hodgkin's B cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone have been diagnosed with Pneumocystis pneumonia. Pneumocystis pneumonia is a serious infection with a high mortality rate and rapid progression. In these patients, the incidence of Pneumocystis pneumonia varied from 1.4 % to 13 %, according to a comprehensive literature review. The major clinical symptoms were dry cough, fever, tightness in the chest, progressive dyspnea and hypoxemia. The standard method of diagnosis is Pneumocystis detection in broncho alveolar lavage fluid and high-resolution computed tomography can be detected in diffuse interstitial infiltration of both lungs. Trimethoprim/sulfamethoxazole is the main treatment for Pneumocystis pneumonia and most studies have shown that preventive use of trimethoprim/ sulfamethoxazole can help reduce the incidence of Pneumocystis pneumonia. In order to improve the accuracy of diagnosis and the prompt initiation of therapy for treatment and prevention to improve outcomes in these patients, a deeper knowledge of the relationship between rituximab use and the incidence of Pneumocystis pneumonia and the characteristics of Pneumocystis pneumonia in non-human immunodeficiency virusinfected patients with lymphoma is required.\",\"PeriodicalId\":13292,\"journal\":{\"name\":\"Indian Journal of Pharmaceutical Sciences\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Journal of Pharmaceutical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.36468/pharmaceutical-sciences.1185\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36468/pharmaceutical-sciences.1185","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Progress in the Research of Pneumocystis Pneumonia in Non-Human Immunodeficiency Virus-Infected Non-Hodgkin's B-Cell Lymphoma Treated With R-CHOP
Increasing numbers of non-human immunodeficiency virus-infected individuals with non-Hodgkin's B cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone have been diagnosed with Pneumocystis pneumonia. Pneumocystis pneumonia is a serious infection with a high mortality rate and rapid progression. In these patients, the incidence of Pneumocystis pneumonia varied from 1.4 % to 13 %, according to a comprehensive literature review. The major clinical symptoms were dry cough, fever, tightness in the chest, progressive dyspnea and hypoxemia. The standard method of diagnosis is Pneumocystis detection in broncho alveolar lavage fluid and high-resolution computed tomography can be detected in diffuse interstitial infiltration of both lungs. Trimethoprim/sulfamethoxazole is the main treatment for Pneumocystis pneumonia and most studies have shown that preventive use of trimethoprim/ sulfamethoxazole can help reduce the incidence of Pneumocystis pneumonia. In order to improve the accuracy of diagnosis and the prompt initiation of therapy for treatment and prevention to improve outcomes in these patients, a deeper knowledge of the relationship between rituximab use and the incidence of Pneumocystis pneumonia and the characteristics of Pneumocystis pneumonia in non-human immunodeficiency virusinfected patients with lymphoma is required.
期刊介绍:
The Indian Journal of Pharmaceutical Sciences (IJPS) is a bi-monthly Journal, which publishes original research work that contributes significantly to further the scientific knowledge in Pharmaceutical Sciences (Pharmaceutical Technology, Pharmaceutics, Biopharmaceutics, Pharmacokinetics, Pharmaceutical/Medicinal Chemistry, Computational Chemistry and Molecular Drug Design, Pharmacognosy and Phytochemistry, Pharmacology and Therapeutics, Pharmaceutical Analysis, Pharmacy Practice, Clinical and Hospital Pharmacy, Pharmacovigilance, Pharmacoepidemiology, Pharmacoeconomics, Drug Information, Patient Counselling, Adverse Drug Reactions Monitoring, Medication Errors, Medication Optimization, Medication Therapy Management, Cell Biology, Genomics and Proteomics, Pharmacogenomics, Bioinformatics and Biotechnology of Pharmaceutical Interest). The Journal publishes original research work either as a Full Research Paper or as a Short Communication. Review Articles on current topics in Pharmaceutical Sciences are also considered for publication by the Journal.